DOES FRAILTY CONTRIBUTE TO HIGHER HEALTH CARE EXPENDITURES?

Por Sirven, N., Rapp, T., Herr, M.
Publicado no Innov Aging (2017)

COMORBIDITY, COGNITIVE, FUNCTIONAL, AND FRAILTY STATUS: SIMILARITIES OF THEIR LEVELS AND OVERLAPS

Por Zekry, D., Gondo, Y., Herr, M., Parker, M.G., Herrmann, F.R., Andersen-Ranberg, K.
Publicado no Innov Aging (2017)

Health insurance coverage among persons with AIDS: results from a multistate surveillance project.

Por Diaz, T, Chu, S Y, Conti, L, Nahlen, B L, Whyte, B, Mokotoff, E, Shields, A, Checko, P J, Herr, M, Mukhtar, Q
Publicado em 1994

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer

Por Hezel, A F, Noel, M S, Allen, J N, Abrams, T A, Yurgelun, M, Faris, J E, Goyal, L, Clark, J W, Blaszkowsky, L S, Murphy, J E, Zheng, H, Khorana, A A, Connolly, G C, Hyrien, O, Baran, A, Herr, M, Ng, K, Sheehan, S, Harris, D J, Regan, E, Borger, D R, Iafrate, A J, Fuchs, C, Ryan, D P, Zhu, A X
Publicado em 2014

Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile

Por Futatsugi, K., Huard, K., Kung, D. W., Pettersen, J. C., Flynn, D. A., Gosset, J. R., Aspnes, G. E., Barnes, R. J., Cabral, S., Dowling, M. S., Fernando, D. P., Goosen, T. C., Gorczyca, W. P., Hepworth, D., Herr, M., Lavergne, S., Li, Q., Niosi, M., Orr, S. T. M., Pardo, I. D., Perez, S. M., Purkal, J., Schmahai, T. J., Shirai, N., Shoieb, A. M., Zhou, J., Goodwin, B.
Publicado no Medchemcomm (2016)